All In Biotech

Drug Trial Radar · NCT07354516

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

A Masked, Randomized, Prospective Study of QLS-111-FDC in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

64

Actual

Start

Mar 18, 2026

Primary completion

Jul 22, 2026

Study completion Jul 22, 2026

Sponsor

Lead sponsor
Qlaris Bio, Inc.Industry
Sponsor type
Industry
First posted
Jan 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Conditions

  • OAG - Open-Angle Glaucoma
  • OHT - Ocular Hypertension

Interventions

  • QLS-111-FDCCombination product

    QLS-111-FDC, a PF FDC administered by topical ophthalmic (TO) application for 14 days in the evening (QPM) in both eyes (OU).

  • Latanoprost (0.005%)Drug

    PF latanoprost administered by TO application for 14 days QPM OU.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in IOPTime frame: Over 15 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shettle Eye Research

    Largo, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.